OmniAb

OmniAb

Life Sciences Tools & Services
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

$670.2M

Market Cap • 9/25/2026

2012

(14 years)

Founded

2022

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,6

P/S

17,4

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,1

EPS

—

Market Cap

Market Cap

670,2M

EV

637,2M

EV/Revenue

16,6

EV/EBITDA

-39

EV/EBIT

-13,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,1%

Total Yield

-0,1%

Payout

0%

Retained Earnings

-179,7M

Profitability

Gross Margin

98,3%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

113,2%

Capex/Revenue

1,2%

Capex/D&A

1,5%

Capex/OCF

-2,6%

SBC/OCF

—

% PPE

7,9%

% Goodwill

28,9%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

2

Debt/Equity

0%

Current Ratio

4,8

Quick Ratio

4,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium